Sun Pharma Advanced Research Company Ltd. (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872, "SPARC") today announced submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA). The IND application supports the next phase of development of SBO-154 which has completed the required IND-enabling preclinical studies with favorable results. A global phase 1 dose-escalation and expansion study has been planned to evaluate SBO-154 in treatment of solid tumors.
"SBO-154, our first ADC is ready to advance in phase 1 with this IND submission, and this is an important milestone for SPARC as we hope to improve lives of cancer patients globally." said Anil Raghavan, CEO of SPARC.
Shares of Sun Pharma Advanced Research Company Limited was last trading in BSE at Rs. 148.00 as compared to the previous close of Rs. 152.00. The total number of shares traded during the day was 148020 in over 2241 trades.
The stock hit an intraday high of Rs. 152.60 and intraday low of 144.80. The net turnover during the day was Rs. 21919122.00. |
